Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Cannabinoid CB1 inverse agonists suppress food-motivated behaviors, but may also induce psychiatric effects such as depression and anxiety. To evaluate behaviors potentially related to anxiety, the present experiments assessed the CB1 inverse agonist AM251 (2.0 – 8.0 mg/kg), the CB1 antagonist AM4113 (3.0 – 12.0 mg/kg), and the benzodiazepine inverse agonist FG-7142 (10.0 – 20.0 mg/kg), using the open field test and the elevated plus maze. Although all three drugs affected open field behavior, these effects were largely due to actions on locomotion. In the elevated plus maze, FG-7142 and AM251 both produced anxiogenic effects. FG-7142 and AM251 also significantly increased c-Fos activity in the amygdala and nucleus accumbens shell. In contrast, AM4113 failed to affect performance in the plus maze, and did not induce c-Fos immunoreactivity. The weak effects of AM4113 are consistent with biochemical data showing that AM4113 induces little or no intrinsic cellular activity. This research may lead to the development of novel appetite suppressants with reduced anxiogenic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“…reports that CB1 receptor tone is generated within the amygdala in response to stressful or anxietyinducing stimuli (Kathuria et al., 2003), and that elevated anandamide levels in mouse amygdala were observed following exposure to a tone that was paired with footshock (Marsicano et al., 2002).”
BackgroundEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 1×
“Clinical trials with CB1 inverse agonists rimonabant and taranabant have shown these drug to be effective at reducing body weight and waist circumference (Curioni and Andre, 2006; Despres et al., 2005; Pi-Sunyer et al., 2006;VanGaal et al., 2005;Addyet al., 2008).”
BackgroundModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 2×
“…are consistent with previous reports that CB1 receptor tone is generated within the amygdala in response to stressful or anxietyinducing stimuli (Kathuria et al., 2003), and that elevated anandamide levels in mouse amygdala were observed following exposure to a tone that was paired with…”
ResultStimulus-transcription coupling in neurons: role of cellular immediate-early genes
Morgan, J. I., & Curran, T. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90096-9 · Cited by 969 · cited 2×
“, 1992), because c-Fos is inducible by a wide array of pharmacological treatments and external stimuli (Morgan and Curran, 1989), and also because c-Fos is expressed in a region- and cell-specific manner that depends upon the type of stimulus (Wisden et al.”
BackgroundActivation of Corticotropin-Releasing Factor in the Limbic System During Cannabinoid Withdrawal
Rodrı́guez de Fonseca, F., Carrera, M. R. A., Navarro, M., Koob, G. F., & Weiss, F. (1997) · Science · doi:10.1126/science.276.5321.2050 · Cited by 499 · cited 2×
“This pattern of c-Fos immunoreactivity was similar to that observed previously using a different CB1 inverse agonist, SR141716 (Alonso et al., 1999; Rodriguez de Fonseca et al., 1997).”
BackgroundInfluentialAnimal models of ‘anxiety’: Where next?
Rodgers, R. J. (1997) · Behavioural Pharmacology · doi:10.1097/00008877-199711000-00003 · Cited by 437 · cited 2×
“…by the fact that drugs may decrease locomotor activity because of an increased level of anxiety-provoked freezing, which is an ethological defensive reaction to threatening situations in rodents (Pellow et al., 1985; Rodgers, 1997; Blanchard et al., 1986), or because of motor suppressant effects.”
BackgroundDefensive behaviors of laboratory and wild Rattus norvegicus..
Blanchard, R. J., Flannelly, K. J., & Blanchard, D. C. (1986) · Journal of comparative psychology · doi:10.1037/0735-7036.100.2.101 · Cited by 405
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354 · cited 2×
“Although the outcomes from these tests are inconsistent (see Akinshola et al., 1999; Haller et al., 2002), many of these animal studies have found CB1 inverse agonists to produce behavioral signs of anxiety (Arevalo et al., 2001; McGregor et al., 1996; Navarro et al., 1997; Rodriguez de Fonseca et…”
BackgroundHaller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241 · cited 4×
“These results are consistent with previous studies of CB1 inverse agonists (Arevalo et al., 2001; McGregor et al., 1996; Navarro et al., 1997; Rodriguez de Fonseca et al., 1996), including studies with AM251 in mice (Haller et al., 2004; Rodgers et al., 2005).”
BackgroundResultInfluential
Cited by
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Self-citationSink, K. S., Walker, D. L., Yang, Y., & Davis, M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5274-10.2011 · Cited by 99
Self-citationTsetsenis, T., Younts, T. J., Chiu, C. Q., Kaeser, P. S., Castillo, P. E., & Südhof, T. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112237108 · Cited by 81
Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity
Meye, F. J., Trezza, V, Vanderschuren, L. J. M. J., Ramakers, G. M. J., & Adan, R. A. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.145 · Cited by 76
Gueye, A. B., Pryslawsky, Y., Trigo, J. M., Poulia, N., Delis, F., Antoniou, K., Loureiro, M., Laviolette, S. R., Vemuri, K., Makriyannis, A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw068 · Cited by 74
Self-citation
Metadata
- Authors
- Sink, K. S., Segovia, K. N., Sink, J., Randall, P. A., Collins, L. E., Correa, M., Markus, E. J., Vemuri, V. K., Makriyannis, A., & Salamone, J. D.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 20
- Issue
- 2
- Pages
- 112-122
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W1966109112
- Cited by
- 86
- References
- 9
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. https://app.cochat.ai/papers/10.1016/j.euroneuro.2009.11.002
- The paper
- Sink, K. S., Segovia, K. N., Sink, J., Randall, P. A., Collins, L. E., Correa, M., Markus, E. J., Vemuri, V. K., Makriyannis, A., & Salamone, J. D. (2010). Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2009.11.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.